Evidence map›Paper›PMID 28700653›Full record

ArticlePloS one2017

Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus.

Kevin M Wheelock, Jian Cai, Helen C Looker, Michael L Merchant, Robert G Nelson, Gudeta D Fufaa, E Jennifer Weil, Harold I Feldman, Ramachandran S Vasan, Paul L Kimmel and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Bradykinin Type 2 Receptor Deficiency Reshapes Acute Neuroinflammation and Improves Cell Survival after Ischemic Stroke in Diabetic Mice.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  2. Review
  3. Review
  4. Diabetic kidney disease in children and adolescents: an update.Pediatric nephrology (Berlin, Germany) · 2022
    Review
  5. Reliable measurement of plasma kinin peptides: Importance of preanalytical variables.Research and practice in thrombosis and haemostasis · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Kevin M WheelockNational Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, United States of America.
Jian CaiUniversity of Louisville, Louisville, Kentucky, United States of America.
Helen C LookerNational Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, United States of America.
Michael L MerchantUniversity of Louisville, Louisville, Kentucky, United States of America.
Robert G NelsonNational Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, United States of America.ORCID http://orcid.org/0000-0001-7307-3786
Gudeta D FufaaNational Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, United States of America.
E Jennifer WeilNational Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, United States of America.
Harold I FeldmanUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Ramachandran S VasanBoston University School of Medicine, Boston, United States of America.
Paul L KimmelNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, United States of America.
Brad H RovinOhio State University, Columbus, Ohio, United States of America.
Michael MauerUniversity of Minnesota, Minneapolis, Minnesota, United States of America.
Jon B KleinUniversity of Louisville, Louisville, Kentucky, United States of America.
CKD Biomarkers Consortium
National Institute of Diabetes and Digestive and Kidney Diseases · USUniversity of Louisville · USBoston University · USThe Ohio State University · USUniversity of Minnesota · USUniversity of Pennsylvania · US

Funding

Epidemiology, Pathophysiology and Treatment of Diabetic NephropathyZIADK069062 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI NELSON, ROBERT G · 2009 to 2023
$10.1M
Proteomic Approach to CKD Biomarker Discovery and ValidationU01DK085689 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI CORESH, JOSEF · 2009 to 2019
$5.6M
Urinary Biomarkers of Chronic Kidney Disease Pathology and ProgressionU01DK085660 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT, WAIKAR, SUSHRUT S. · 2009 to 2019
$5.3M
"Validation of Novel CKD Biomarkers in CRIC"U01DK085649 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN, LIU, KATHLEEN D · 2009 to 2013
$4.4M
The New York CKD Biomarker Discovery ProgramU01DK085688 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BOTTINGER, ERWIN P. · 2009 to 2013
$3.0M
Urinary Biomarkers in Biopsy Defined Early Nephropathy in Types 1 and 2 DiabetesU01DK085651 · NIDDK · UNIVERSITY OF MINNESOTA · PI MAUER, S. MICHAEL · 2009 to 2013
$2.2M
Discovery & Validation of Biomarkers of Kidney PathologyU01DK096927 · NIDDK · OHIO STATE UNIVERSITY · PI ROVIN, BRAD H · 2013 to 2017
$2.0M
Forecasters of futute and progressive CDK in patients with microvascular glomerulU01DK085673 · NIDDK · OHIO STATE UNIVERSITY · PI KLEIN, JON, ROVIN, BRAD H · 2009 to 2013
$2.0M
NIDDK NIH HHS U01 DK085649NIDDK NIH HHS U01 DK085651NIDDK NIH HHS U01 DK085660NIDDK NIH HHS U01 DK085673NIDDK NIH HHS U01 DK085688NIDDK NIH HHS U01 DK085689NIDDK NIH HHS U01 DK096927
6 · The paper itself

Abstract

objectiveTo examine the association of bradykinin and related peptides with the development of diabetic nephropathy lesions in 243 participants with type 1 diabetes (T1D) from the Renin-Angiotensin System Study who, at baseline, were normoalbuminuric, normotensive and had normal or increased glomerular filtration rate (GFR).

designPlasma concentrations of bradykinin and related peptides were measured at baseline by quantitative mass spectrometry. All participants were randomly assigned at baseline to receive placebo, enalapril or losartan during the 5 years between kidney biopsies. Kidney morphometric data were available from kidney biopsies at baseline and after 5 years. Relationships of peptides with changes in morphometric variables were assessed using multiple linear regression after adjustment for age, sex, diabetes duration, HbA1c, mean arterial pressure, treatment assignment and, for longitudinal analyses, baseline structure.

resultsBaseline median albumin excretion rate of study participants was 5.0 μg/min, and mean GFR was 128 mL/min/1.73 m2. After multivariable adjustment, higher plasma concentration of bradykinin (1-8) was associated with greater glomerular volume (partial r = 0.191, P = 0.019) and total filtration surface area (partial r = 0.211, P = 0.010), and higher bradykinin (1-7) and hyp3-bradykinin (1-7) were associated with lower cortical interstitial fractional volume (partial r = -0.189, P = 0.011; partial r = -0.164, P = 0.027 respectively). In longitudinal analyses, higher bradykinin was associated with preservation of surface density of the peripheral glomerular basement membrane (partial r = 0.162, P = 0.013), and for participants randomized to losartan, higher hyp3-bradykinin (1-8) was associated with more limited increase in cortical interstitial fractional volume (partial r = -0.291, P = 0.033).

conclusionsHigher plasma bradykinin and related peptide concentrations measured before clinical onset of diabetic nephropathy in persons with T1D were associated with preservation of glomerular structures, suggesting that elevations of these kinin concentrations may reflect adaptive responses to early renal structural changes in diabetic nephropathy.

Indexed as

AdolescentAdultAgedBradykininDiabetes Mellitus, Type 1Diabetic NephropathiesFemaleGlomerular Filtration RateHumansKidneyKidney GlomerulusMaleMiddle AgedRenin-Angiotensin SystemYoung AdultBradykinin

Identifiers

PMID28700653
PMCPMC5507314
OpenAlexW2735708922

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.